Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience

Figures & data

Table 1. Characteristics of our population at baseline.

N. of patients	50
	N (%)
Female	35 (70)
Autoimmune thyroiditis	11 (22)
Cardiometabolic comorbidities	7 (14)
Atopic dermatitis	5 (10)
Severe (SALT score 50–94)	20 (40)
Very severe (SALT score 95–100)	30 (60)
	Mean (SD)
Age, years	41.86 (12.70)
Disease duration, years	15.98 (12.81)
BMI, kg/m^2	23.40 (3.02)
Mean SALT at baseline	84.38 (20.42)

Note: SALT: Severity of Alopecia Tool; BMI: body mass index; SD: standard deviation.

Figure 1. (a) Percentages of patients who achieved an absolute SALT score of 20 or less throughout the study period; (b) patterns of clinical response to baricitinib, including early-, gradual- and late-responders.

Figure 2. Clinical presentation of a 64-year-old woman before (a) starting baricitinib and after 36 weeks of treatment (b).

Data availability statement

Additional data supporting the findings of this study are available from the Corresponding Author on reasonable request.